Capitol Hill drug pricing reform opponents among the biggest beneficiaries of pharma funds

Capitol Hill drug pricing reform opponents among the biggest beneficiaries of pharma funds
By Ahmed Aboulenein and Carl O’Donnell
(Reuters) – Democratic Party lawmakers holding up proposed drug pricing reforms are among the largest beneficiaries of the pharmaceutical industry’s push to stave off price cuts, a Reuters analysis of public lobbying and campaign data shows.

Read the source article at aol.com
2021-10-25 13:08:44